Pathoquest_logo
  • About Us
    • Why PathoQuest
    • Leadership Team
    • Strategic Partnerships
    • Client Testimonials
    • Careers
  • Modalities
    • mAbs and Recombinant Proteins
    • Viral Vectors
    • Cell Therapies
    • Vaccines
    • RNA Therapies
    • Cultivated Meat
  • Services
    • Adventitious Virus Testing
    • In Vivo Replacement
    • Cell Line Characterization
    • Identity Confirmation
    • HLA Genotyping
    • Integration Site Analysis
    • Raw Material Testing
  • iDTECT® Platform
  • 3Rs
  • Quality & Regulatory
    • Quality
    • Regulatory
  • Resources
    • Publications
    • Brochures and Posters
    • Webinars and Talks
    • Our One-Minute Series on NGS
  • News
  • Contact

Attend our NEXT-GEN BIOSAFETY MASTERCLASS I Next Generation Sequencing in Biosafety Testing: From Regulation to Routine Use I SEPTEMBER 10, 2026 in Paris (France)

by Sabrina | Feb 13, 2026 | News, Press Release

Next-Gen Biosafety Masterclass Next Generation Sequencing (NGS) in Biosafety Testing: From Regulation to Routine Use SEPTEMBER 10, 2026 in Paris (France) PathoQuest is pleased to announce the upcoming Next-Gen Biosafety Masterclass: "Next Generation Sequencing (NGS)...

PRESS RELEASE: PathoQuest to Join Charles River Laboratories, Accelerating the Future of NGS-Based GMP Biosafety Testing Worldwide

by Delphine Gricourt | Jan 12, 2026 | News

PRESS RELEASE   PathoQuest to join Charles River Laboratories, Accelerating the Future of NGS-based GMP Biosafety Testing Worldwide   Paris, France — January 12, 2026   PathoQuest, a pioneer and global leader in Next Generation Sequencing (NGS)–based...

PathoQuest CEO Jean-François Brepson, Featured on Molecule to Market Podcast

by Sabrina | Nov 26, 2025 | News

 PathoQuest CEO Jean-François Brepson, Featured on Molecule to Market Podcast. 📅 NOV 26, 2025 From Pharma to CRO entrepreneur. Jean-François Brepson, CEO of PathoQuest, joined the Molecule to Market podcast for a conversation about his journey from global pharma...

FDA Announces Plan to Phase Out Animal Testing Requirement for mAbs and Other Drugs

by Sabrina | Apr 17, 2025 | News

FDA Announces Plan to Phase Out Animal Testing Requirement for mAbs and Other Drugs 📅 April 10, 2025​ What the FDA announced:​ Plan to phase out animal testing requirements for monoclonal antibodies and other drugs​ Reinforcement of the 3R principles: Replace, Reduce,...

A NEW publication from a study conducted by AVDTWG and the FDA confirms NGS as a reliable technology for Adventitious Virus Detection

by Sabrina | Apr 15, 2025 | News

A New Publication Confirms NGS as a Reliable Technology for Adventitious Virus Detection 𝐍𝐄𝐖 𝐏𝐔𝐁𝐋𝐈𝐂𝐀𝐓𝐈𝐎𝐍: A comparative study conducted by members of the Advanced Virus Detection Technologies Working Group (𝐀𝐕𝐃𝐓𝐖𝐆), including participants from industry, contract...

FDA Announces Plan to Phase Out Animal Testing Requirement for mAbs and Other Drugs

by Sabrina | Apr 10, 2025 | News

FDA Announces Plan to Phase Out Animal Testing Requirement for mAbs and Other Drugs 📅 April 10, 2025​ What the FDA announced:​ Plan to phase out animal testing requirements for monoclonal antibodies and other drugs​ Reinforcement of the 3R principles: Replace, Reduce,...
« Older Entries

Home » News

T: +33 (0)1 70 82 17 90
T: +1 484 212 9360

Copyright © 2026 – PathoQuest | Cookies Policy | Privacy Policy

T: +33 (0)1 70 82 17 90
T: +1 484 212 9360

Copyright © 2026 – PathoQuest | Cookies Policy | Privacy Policy

Cleantalk Pixel
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}

Explore our full library of scientific resources

Access our latest thinking

Name(Required)
By submitting this form, PathoQuest will use the personal data you provide to handle your request. Read our Privacy Notice for more information.(Required)